North Chicago, Ill.), or UBI (United Biomedical, Inc., Hauppauge, York, N.Y.). The choice of assay system was determined by the center from which the samples originated.
RNA was extracted from 200 l of serum or plasma by the guanidinium isothiocyanate-phenol-chloroform method (5) with minor modifications. A combined reverse transcriptionlinked PCR was used to amplify cDNA. Five microliters of RNA was added to a thin-walled 250-l tube (Perkin-Elmer Corp., Norwalk, Conn.) containing 1ϫ PCR buffer (10 mM Tris-HCl [pH 8.3] , 50 mM KCl, 0.01% gelatin, 1.5 mM MgCl 2 ) and 0.2 M outer primers for the 5Ј noncoding region (NCR) (3) . The tube was heated to 95ЊC for 5 min and was cooled to 20ЊC before the addition of 200 M (each) dATP, dCTP, dTTP, and dGTP; 1.25 U of Taq DNA polymerase (Boehringer Mannheim, GmbH, Biochemica, Mannheim, Germany); 100 U of Moloney murine leukemia virus reverse transcriptase (Gibco BRL Life Technologies, Ltd., Paisley, Scotland), and 10 U of RNasin (Promega Corp., Madison, Wis.). Reverse transcription was performed at 42ЊC for 45 min before denaturation at 92.5ЊC for 20 s. Thereafter, amplification was performed for 35 cycles in a Perkin-Elmer 9600 thermal cycler, with cycling temperatures and times of 50ЊC for 30 s, 72ЊC for 45 s, and 92.5ЊC for 20 s. A final extension step of 72ЊC for 7 min was also included. Three microliters of the PCR product from the outer reaction was removed and transferred to a thin-walled tube containing fresh reagents and 1.2 M inner primers (3) and was subjected to a further 35 cycles of amplification. The PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The size of the PCR product was 251 bp.
HCV typing was performed by the method of McOmish et al. (12) . Briefly, 5-l aliquots of the nested PCR product were digested with (i) 1 U each of RsaI and HaeIII and (ii) 1 U each of MvaI and HinfI (Boehringer Mannheim, GmbH, Biochemica) in the appropriate buffer for 2 h at 37ЊC. The digested products were separated by electrophoresis on a 13% polyacrylamide gel at 8 W for 2 h. The DNA fragments were visualized by silver staining, which is a sensitive and rapid method and obviates the need to use a radioactively labelled PCR product (19) (Qiagen protocol; Qiagen Inc., Chatsworth, Calif.). The banding patterns were compared with those described by McOmish et al. (12) . Figure 1A shows the banding pattern consistently produced by type 5. Type 1 produced two different electropherograms ( Samples from four patients (three of whom were blood donors) which were typed with MvaI-HinfI as either type 3 or 4 showed an unusual restriction pattern on digestion with RsaIHaeIII (Fig. 1C ). It was therefore not possible to distinguish between these types. McOmish et al. (12) and Dusheiko et al. (7) have reported similar anomalous restriction fragment length polymorphism (RFLP) banding patterns for a few patients from Egypt and Iraq. Bands produced by RsaI-HaeIII digestion were larger than expected because of the loss of a normally conserved RsaI site within the 5Ј NCR with an A 3 T or A 3 C change at position Ϫ176 (12) . Sequence analysis of cloned PCR products from three of the four cases identified in this study confirmed the loss of the RsaI site. However, the base change at this site was a T 3 A substitution at position Ϫ177 (results not shown). Further sequence analysis of other regions of this genome needs to be done to determine if it is a subtype of type 3 or 4, or an entirely new type.
Of the 130 samples examined, 51 (39%) were identified as type 5 and 43 (33%) were identified as type 1 (Table 1 ). These two genotypes represent 72% (57 of 79) of the samples from the blood donor population and 89% (17 of 19) of the samples from patients with liver disease. Thus, type 5 may be associated with severe liver disease, as has been found with type 1b (17) . However, many of the other known genotypes have also been found in patients with severe disease (8) and the prevalence of type 5 may simply reflect the predominant genotype of the region.
Until recently, type 5 was reported to occur only in South Africa, but Stuyver et al. (23) have now identified type 5 in Gabonese and Benelux serum samples. Thus, the distribution of type 5 may not be as restricted as previously reported. It is noteworthy, however, that no type 5 was found in samples from Egypt (1), Zaire (12, 20) , and Burundi (22) . In all of these countries, type 4 was most commonly found, indicating its widespread distribution in North and Central Africa. We have shown that type 4 rarely occurs in South Africa (3 of 130 samples) ( Table 1) . No blood donors were infected with type 4, and patients with chronic renal failure, who received on average 22 blood transfusions, were infected with types 1 and 5 only, reflecting the predominance of these genotypes in the blood donor population in South Africa. Type 4 was seen only in the hemophiliac population. The reason for this is unclear but may be related to the number of pooled blood products administered to this group. Type 1 was found to be the second most common genotype in South Africa (33%) ( Table 1) . Previous studies have shown that type 1 has a global distribution (8) but, with the exception of one case in Ghana (7), has not been found in Africa. Ours is the first report of a high prevalence of type 1 in Africa. The introduction of type 1 into South Africa may have been brought about by travel of infected individuals between Europe and the United States and South Africa or importation of blood products from these countries. The recent description of types 7, 8, and 9 indicates over 96% homology in the 5Ј NCR to type 1 (although other regions of the genome are very different) (25) , which could result in the generation of the same RFLP pattern as type 1. However, type-specific PCR (15) of a random selection of samples identified in this study by RFLP analysis as type 1 showed all to be either type 1a (57 bp) or type 1b (144 bp). The identification of type 1 by RFLP probably reflects the true prevalence of this genotype in the region.
In this study, HCV types 2 and 3 were found in 13.8 and 7.7% of cases, respectively (Table 1) . Although there was an apparent higher prevalence of type 3 in Kwa Zulu-Natal blood donors (Natal Blood Transfusion Service, 17%) than in blood donors from the northern and southwestern parts of the country (South African Blood Transfusion Service, 3%; Western Province Blood Transfusion Service, 7%), this difference was not statistically significant.
It has previously been shown that patients infected with type 1 respond poorly to therapy compared with those infected with type 2 (9, 26) . Since type 5 obviously has a high prevalence in the South African community, it will be important to determine the response of this genotype to interferon therapy. Further, in order to determine if type 5 can be considered an African genotype (23) like type 4, prevalence studies in other African countries, especially in southern Africa, need to be undertaken. 
